GRAIL Galleri Consultant # 4272
GRAILSalary not specified
Full Time
Entry Level & New Grad
About GRAIL
GRAIL focuses on improving cancer detection through advanced blood tests that identify cancer at its earliest stages, enhancing treatment success rates. The company utilizes high-intensity sequencing to analyze tumor genome data, employing algorithms and deep learning to extract actionable information for early cancer detection. GRAIL differentiates itself from competitors by its commitment to large-scale clinical studies that validate the effectiveness of its tests. The primary goal is to reduce global cancer mortality by enabling early diagnosis, making the disease more treatable.
Menlo Park, CaliforniaHeadquarters
2016Year Founded
$1,765.5MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees
Benefits
Outstanding People - Join a team of passionate and dedicated professionals, committed to collaboration, education, and proactive problem-solving.
Strong Compensation - We offer competitive salaries and savings plans to provide for long-term financial planning.
Complete Health Coverage - Take advantage of comprehensive health coverage, with medical, dental and vision, to keep you and your family healthy.
Work-Life Balance - Make everyday life more manageable with flexible time off – we trust you to do great work and take time for yourself.
Risks
Potential overdiagnosis could impact the perceived value of GRAIL's tests.
Significant net losses may affect investor confidence and long-term sustainability.
High test costs may limit accessibility in markets with less healthcare funding.
Differentiation
GRAIL uses high-intensity sequencing for early cancer detection via blood tests.
The Galleri test screens for over 50 cancers with a single blood draw.
GRAIL's tests are supported by large-scale clinical studies ensuring reliability.
Upsides
Collaborations with platforms like Function Health expand Galleri test accessibility.
Revenue from Galleri grew 52% year-over-year, indicating strong market demand.
GRAIL's technology aligns with trends in personalized and preventative medicine.
Funding
Total raised$1.77 B
Latest valuation$8.00 B
StageACQUISITION
ACQUISITION
8/31/2020$8.0 K
$8.00 BSERIES D
4/30/2020$390
$1.95 BSERIES B
10/31/2017$900
$4.50 B$100
$500.00 M